open label uncontrolled clinical trial of immunogenicity and safety of yellow fever vaccine in adults with chronic kidney disease as compared to immunocompetent

living kidney transplantation in a patient with end stage kidney disease due to rare juvenile nail patella like renal disease without lmx1b mutation

sodium glucose cotransporter 2 inhibitors in chronic kidney disease and type 2 diabetes a narrative review

A new clinical trial funded by Breakthrough T1D is testing islet cell transplantation with Eledon Pharmaceuticals' tegoprubart in individuals with type 1 diabetes and chronic kidney disease. This marks a significant inclusion as nearly one in three people with type 1 diabetes develop chronic kidney disease, highlighting the need for innovative treatment options.

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and ... City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. Using RNA to interfere with a disease-driving protein is a proven way to address disease targets in the liver. City Therapeutics is one of the companies developing the next-generation of these medicines for a wealth of targets in the rest of the body. With its lead drug candidate in clinical development for cardiovascular indications, the biotech now has $200 million in IPO cash to fund clinical development of that program and others in its pipeline. City is also exploring use of this siRNA for anemia associated with chronic kidney disease and chronic inflammatory disorders, including inflammatory bowel disease. In these indications, elevated hepcidin and iron restriction contribute to the disease. City’s research has attracted collaborators. Bausch + Lomb is working with the biotech to develop RNAi therapies for eye diseases, specifically geographic atrophy. Cambridge, Massachusetts-based City is developing RNA interference (RNAi) drugs, which employ small interfering RNA (siRNA) to target and degrade messenger RNA before it can be translated into a protein that contributes to disease. This modality, also called gene silencing, was pioneered by Alnylam Pharmaceuticals, which sells four FDA-approved RNAi drugs — all for rare diseases stemming from liver proteins.